WO2012016479A1 - 瑞舒伐他汀钙中间体的制备方法 - Google Patents
瑞舒伐他汀钙中间体的制备方法 Download PDFInfo
- Publication number
- WO2012016479A1 WO2012016479A1 PCT/CN2011/075757 CN2011075757W WO2012016479A1 WO 2012016479 A1 WO2012016479 A1 WO 2012016479A1 CN 2011075757 W CN2011075757 W CN 2011075757W WO 2012016479 A1 WO2012016479 A1 WO 2012016479A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- borohydride
- systems
- sodium
- potassium
- cooh
- Prior art date
Links
- 0 CN(*)c1nc([I+]c2ccccc2)c(C(OC)=O)c(-c(cc2)ccc2F)n1 Chemical compound CN(*)c1nc([I+]c2ccccc2)c(C(OC)=O)c(-c(cc2)ccc2F)n1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Definitions
- the invention relates to a preparation method of a rosuvastatin calcium intermediate, in particular to a preparation method of the compound represented by the formula I,
- Rosuvastatin calcium chemical name: (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-fluorenyl-N-methanesulfonamide -5-pyrimidine] -3,5-dihydroxy-6-heptenoate, a new generation of statins that fully synthesize a single enantiomer, belonging to the HMG-CoA reductase inhibitor, which reduces elevation Low-density cholesterol, total cholesterol, triglyceride, and apoprotein B concentrations, while increasing the concentration of high-density cholesterol. It can be used for the treatment of primary hypercholesterolemia and mixed lipodystrophy and homozygous familial hypercholesterolemia. Its structural formula is as follows:
- the compound of the formula I relates to an important intermediate for the preparation of rosuvastatin calcium, and the European patent EP521471 discloses a method for synthesizing rosuvastatin calcium, wherein the correction page is involved (rule 91) article)
- the preparation method of the inter-body, the main steps of the process are as follows:
- the technical problem to be solved by the present invention is to provide a method for preparing intermediate compound I of rosuvastatin calcium which is low in cost and suitable for industrial production, in order to overcome the drawbacks of the prior art.
- R is a C1 to C5 alkyl group
- the metal compound described in the step (1) is LiOH or a hydrate thereof.
- the specific reducing agent described in the step (2) is a borane or a borohydride and a Lewis acid reduction system.
- the borohydride and Lewis acid reduction system is potassium borohydride and boron trifluoride etherate system, sodium borohydride and boron trifluoride etherate system, lithium borohydride and boron trifluoride etherate system, potassium borohydride and H 2 S04 system, potassium borohydride and ZnCl 2 system, potassium borohydride and A1C1 3 system, potassium borohydride and 12 systems, potassium borohydride and CF 3 COOH system, potassium borohydride and HCOOH systems, potassium borohydride and MsOH system, Potassium borohydride and CH 3 COOH systems, potassium borohydride and NiCl 2 systems, zinc borohydride and H 2 S04 systems, zinc borohydride and ZnCl 2 systems, zinc borohydride and A1C1 3 systems, zinc borohydride and 12
- the present invention relates to a compound of the formula III which is a novel compound having a melting point of 211.0 ° C to 212.35 ° C and which has a very important effect on the realization of the present invention.
- the reaction system is quenched by slow dropwise addition of decyl alcohol, and the solvent is removed under reduced pressure (temperature: 30 to 35 ° (:, vacuum degree: 250 to 350 Pa), and 40 ml of water is added to the remaining solid, and stirred.
- the pH of the system was adjusted to 2 to 3, and the aqueous phase was extracted three times with 200 ml of tert-butyl ether.
- the mixture was concentrated under reduced pressure (temperature 30 to 35 ° C, vacuum: 250 to 350 Pa) to give a crude compound of formula I as a white solid.
- the decyl ether-n-hexane mixture (volume ratio: 1:10) was recrystallized to obtain 6.7 g of a product having a content of 99.0% and a yield of 96.4 ° /.
- the compound of the formula 11-2 was added to 39.58 (11; : 99.5%), LiOH ⁇ H 2 0 4.6 g was added, and 150 g of purified water and 130 g of decyl alcohol were further added.
- the mixture is heated to 60 ⁇ 70 ° C under stirring, and the reaction of the raw materials is completed in TLC, and the solvent is removed under reduced pressure (temperature: 30 to 35 ° C, vacuum degree: 250 to 350 Pa), and 150 ml of purified water is added to the remaining solid.
- reaction system is quenched by slowly adding sterol, and the solvent is removed by distillation under reduced pressure (temperature: 30 to 35 ° C, vacuum degree: 250 to 350 Pa), and 40 ml of water is added to the remaining solid.
- the reaction system is quenched by slowly adding sterol, and the solvent is removed under reduced pressure (temperature: 30 to 35 ° C, vacuum degree: 250 to 350 Pa), and 40 ml of water is added to the remaining solid, and stirred.
- the pH of the system was adjusted to 2 to 3, and the aqueous phase was extracted three times with 200 ml of tert-butyl ether.
- the mixture was concentrated under reduced pressure (temperature: 30-35 ° C, vacuum: 250-350 Pa).
- the product was recrystallized from a mixture of tert-butyl ether and n-hexane (volume ratio: 1:10) to give the product 6.8 g (yield: 99.0%, yield: 97.8).
- reaction system is quenched by slowly adding sterol, and the solvent is removed under reduced pressure (temperature: 30-35 ° C, vacuum degree: 250-350 Pa), 40 ml of water is added to the remaining solid, and stirred.
- the pH of the system was adjusted to 2 to 3, and the aqueous phase was extracted 3 times with 200 ml of terpene ether. Concentrated under reduced pressure (temperature is 30 ⁇ 35 °C, true correction page (rule 91) 6479
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11814062.3A EP2602250B1 (en) | 2010-08-04 | 2011-06-15 | Method for preparing rosuvastatin calcium intermediate |
KR1020137003414A KR20130027568A (ko) | 2010-08-04 | 2011-06-15 | 로수바스타틴칼슘 중간체의 제조방법 |
JP2013522078A JP5628427B2 (ja) | 2010-08-04 | 2011-06-15 | ロスバスタチンカルシウム中間物の調製方法 |
US13/757,846 US8703944B2 (en) | 2010-08-04 | 2013-02-03 | Method for preparing rosuvastatin calcium intermediate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102449638A CN101955463B (zh) | 2010-08-04 | 2010-08-04 | 瑞舒伐他汀钙中间体的制备方法 |
CN201010244963.8 | 2010-08-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/757,846 Continuation-In-Part US8703944B2 (en) | 2010-08-04 | 2013-02-03 | Method for preparing rosuvastatin calcium intermediate |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012016479A1 true WO2012016479A1 (zh) | 2012-02-09 |
Family
ID=43483082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/075757 WO2012016479A1 (zh) | 2010-08-04 | 2011-06-15 | 瑞舒伐他汀钙中间体的制备方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8703944B2 (zh) |
EP (1) | EP2602250B1 (zh) |
JP (1) | JP5628427B2 (zh) |
KR (1) | KR20130027568A (zh) |
CN (1) | CN101955463B (zh) |
WO (1) | WO2012016479A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101955463B (zh) * | 2010-08-04 | 2012-01-04 | 重庆博腾制药科技股份有限公司 | 瑞舒伐他汀钙中间体的制备方法 |
CN102757318B (zh) * | 2011-04-29 | 2015-06-24 | 上海医药工业研究院 | 一种阿利克伦中间体的制备方法 |
CN102351662B (zh) * | 2011-08-17 | 2014-02-05 | 常州市华人化工有限公司 | (s)-(+)-2-甲氧基甲氧基-1-丙醇的制备方法 |
CN102617481A (zh) * | 2012-03-16 | 2012-08-01 | 湖南欧亚生物有限公司 | 一种瑞舒伐他汀钙的制备方法 |
CN103044339A (zh) * | 2012-10-15 | 2013-04-17 | 武汉市江润精细化工有限责任公司 | 瑞舒伐他汀钙中间体的制备方法 |
CN103864697A (zh) * | 2012-12-11 | 2014-06-18 | 润泽制药(苏州)有限公司 | 瑞舒伐中间体主链醇的制备方法 |
CN103319419A (zh) * | 2013-06-18 | 2013-09-25 | 复旦大学 | 一种4-对氟苯基6-异丙基-2-(n-甲基甲磺酰胺基)嘧啶-5-羧酸的制备方法 |
CN103570762B (zh) * | 2013-11-25 | 2015-12-09 | 复旦大学 | ((4-对氟苯基-6-异丙基-2-(n-甲基甲磺酰胺基)-5-吡啶基)甲基)三苯基鏻盐的制备方法 |
CN106632078B (zh) * | 2016-11-11 | 2019-05-07 | 上海雅本化学有限公司 | 一种瑞舒伐他汀钙中间体的精制方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0521471A1 (en) | 1991-07-01 | 1993-01-07 | Shionogi Seiyaku Kabushiki Kaisha | Pyrimidine derivatives as HMG-CoA reductase inhibitors |
CN1958593A (zh) * | 2005-11-03 | 2007-05-09 | 上海医药工业研究院 | 一种用于合成瑞舒伐他汀钙的中间体的制备方法 |
CN101376647A (zh) * | 2007-08-31 | 2009-03-04 | 中山奕安泰医药科技有限公司 | 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法 |
CN101955463A (zh) * | 2010-08-04 | 2011-01-26 | 重庆博腾制药科技股份有限公司 | 瑞舒伐他汀钙中间体的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ531033A (en) * | 2001-07-13 | 2005-07-29 | Astrazeneca Uk Ltd | Preparation of a 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound or analogous aminopyrimidine compounds |
EA200401533A1 (ru) * | 2002-05-21 | 2005-06-30 | Ранбакси Лабораторис Лимитед | Способ получения росувастатина |
WO2004103977A2 (en) * | 2003-05-21 | 2004-12-02 | Ciba Specialty Chemicals Holding Inc. | Process for the preparation of pyrimidine derivatives |
HUP0400405A3 (en) * | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
CN1872841A (zh) * | 2005-06-01 | 2006-12-06 | 信谊药厂 | 瑞舒伐他汀钙及其关键中间体的制备方法 |
US7659281B2 (en) * | 2006-04-25 | 2010-02-09 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors |
WO2008059519A2 (en) * | 2006-09-25 | 2008-05-22 | Glenmark Pharmaceuticals Limited | A process for the preparation of intermediates of rosuvastatin |
CN101190897B (zh) * | 2006-11-30 | 2011-05-11 | 天津天士力集团有限公司 | 一种4-(4-氟苯基)-6-异丙基-2-甲胺基嘧啶-5-甲酸酯的合成方法 |
KR101292238B1 (ko) * | 2010-07-01 | 2013-07-31 | 주식회사유한양행 | HMG-CoA 환원효소 억제제 및 그의 중간체의 제조방법 |
-
2010
- 2010-08-04 CN CN2010102449638A patent/CN101955463B/zh active Active
-
2011
- 2011-06-15 KR KR1020137003414A patent/KR20130027568A/ko not_active Application Discontinuation
- 2011-06-15 EP EP11814062.3A patent/EP2602250B1/en not_active Not-in-force
- 2011-06-15 WO PCT/CN2011/075757 patent/WO2012016479A1/zh active Application Filing
- 2011-06-15 JP JP2013522078A patent/JP5628427B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-03 US US13/757,846 patent/US8703944B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0521471A1 (en) | 1991-07-01 | 1993-01-07 | Shionogi Seiyaku Kabushiki Kaisha | Pyrimidine derivatives as HMG-CoA reductase inhibitors |
CN1958593A (zh) * | 2005-11-03 | 2007-05-09 | 上海医药工业研究院 | 一种用于合成瑞舒伐他汀钙的中间体的制备方法 |
CN101376647A (zh) * | 2007-08-31 | 2009-03-04 | 中山奕安泰医药科技有限公司 | 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法 |
CN101955463A (zh) * | 2010-08-04 | 2011-01-26 | 重庆博腾制药科技股份有限公司 | 瑞舒伐他汀钙中间体的制备方法 |
Non-Patent Citations (2)
Title |
---|
See also references of EP2602250A4 * |
SHAO FEI ET AL.: "Improvement in Synthesis Method of the Intermediate of Rosuvastatin", FINE CHEMICALS, vol. 23, no. 2, 2006, pages 192 - 194 * |
Also Published As
Publication number | Publication date |
---|---|
US20130143908A1 (en) | 2013-06-06 |
EP2602250B1 (en) | 2016-03-23 |
EP2602250A4 (en) | 2014-02-26 |
EP2602250A1 (en) | 2013-06-12 |
US8703944B2 (en) | 2014-04-22 |
JP5628427B2 (ja) | 2014-11-19 |
CN101955463A (zh) | 2011-01-26 |
JP2013532693A (ja) | 2013-08-19 |
CN101955463B (zh) | 2012-01-04 |
KR20130027568A (ko) | 2013-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012016479A1 (zh) | 瑞舒伐他汀钙中间体的制备方法 | |
ES2669052T3 (es) | Método de preparación de acetato de ulipristal y sus intermedios | |
WO2013026391A1 (zh) | 嘧菌酯及其合成中专用中间体的合成方法 | |
EP3472169A1 (en) | METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE | |
WO2010035284A2 (en) | An improved process for the preparation of rosuvastatin calcium | |
EP2227465A1 (en) | Crystalline form i of lamivudine and its preparation | |
CN103012260B (zh) | 匹伐他汀钙中间体的制备方法 | |
JP5622842B2 (ja) | アルキルアミン誘導体の製造方法 | |
JP2019023224A (ja) | 2−アミノ−1,3−プロパンジオール化合物およびその塩の製造のための方法 | |
JP5968900B2 (ja) | ロスバスタチン塩の製法 | |
JP2005514459A (ja) | フェンセリン及びその類似体を生成するための方法 | |
WO2013114338A1 (en) | Process for the preparation of vilazodone or its pharmaceutically acceptable salts | |
KR20140017207A (ko) | 로수바스타틴 이소프로필 아민염, 이의 제조 방법 및 이를 이용한 로수바스타틴 헤미칼슘염의 제조방법 | |
WO2009128091A2 (en) | Crystalline form of(7-[4-(4-fluorophenyl)-6-isopropyl-2-(n- methyl-n-methylsulfonylamino)pyrimidin-5-yl]-(3r,5s)- dihydroxy-(e)-6-heptenoic acid intermediate, process for preparing the same and use thereof | |
WO2011021058A1 (en) | Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester | |
CN103044339A (zh) | 瑞舒伐他汀钙中间体的制备方法 | |
WO2011114338A1 (en) | A process for the preparation of highly pure ambrisentan | |
JP5796836B2 (ja) | ピタバスタチンまたはその塩の中間体の製造方法 | |
WO2013185309A1 (zh) | 瑞舒伐他汀钙及其中间体的制备方法 | |
JP2014530248A (ja) | ボセンタンの酸付加塩 | |
CN106854201B (zh) | 一种瑞舒伐他汀钙中间体的纯化方法 | |
EP2502910A1 (en) | Camphorsulfonic salt of a key Montelukast intermediate | |
JP2005145833A (ja) | Syn−1,3−ジオール化合物の製造方法 | |
CN113620920A (zh) | 一种盐酸奥洛他定的制备方法 | |
WO2015003670A1 (en) | A new process for the preparation of elvitegravir |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11814062 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013522078 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137003414 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011814062 Country of ref document: EP |